Close Menu

NEW YORK – Agilent Technologies announced today that it has priced an underwritten, registered public offering of a series of its senior notes, in an aggregate principal amount of $500 million.

In a filing with the US Securities and Exchange Commission, the company said that the notes will mature in September 2029 and will bear interest at an annual rate of 2.750 percent. The offering is expected to close on Sep. 16, and Agilent is expecting net proceeds of approximately $492.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.

NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.

The New York Times reports on how environmental DNA sampling could monitor endangered species.

In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.